Hansa Biopharma reported positive outcomes from a pivotal U.S. phase III trial of imlifidase, an enzyme that rapidly cleaves antibodies to facilitate kidney transplantation in highly sensitized patients on dialysis. The randomized controlled study included 64 patients, showing significantly improved kidney function at 12 months with imlifidase treatment compared to standard desensitization. The therapy, which removes anti-HLA antibodies, may broaden transplant eligibility and reduce wait times for this challenging patient group. Hansa plans a biologics license application submission by year-end.